? GO BACK TO SATURDAY, OCTOBER 17, 2015
17.00-19.00
Oral Communications
9. AF: THROMBOEMBOLIC RISK STRATIFICATION AND ANTICOAGULATION TREATMENT
Chairmen: J. Oldgren / Uppsala, Sweden – T. Potpara / Belgrade, Serbia
Transoesophageal echocardiogram before cardioversion in properly anticoagulated patients with persistent atrial fibrillation
A. Zebrauskaite, A. Aidietis, J. Barysiene, G. Marinskis, D. Petrikonyte / Vilnius, Poland
Efficacy and safety outcomes in 8040 women compared with 13085 men with atrial fibrillation treated with Edoxaban vs Warfarin for an average 2.8 years
R.P. Giugliano, M.L. O’Donoghue, C.T. Ruff, P. Merlini, F. Nordio, L.T. Grip, V. Curt, H. Lanz, M. Mercuri, E. Braunwald / Boston, USA
Efficacy and safety of dabigratran versus acenocumarol in non-valvular atrial fibrillation (NVAF). A real-world single center observational study
C. Podoleanu, I. Coman, C. Tarta, Z.S. Jeremias, A. Trif, I. Grancea, E. Carasca / Tirgu Mures, Romania
Cost-effectiveness of Dabigatran exilate in treatment of atrial fibrillation
G. Galvani, A. Grassetto, D. Mangino, S. Sterlicchio, S. Themistoclakis, A. Venturini, G. Zoffoli / Mestre-Venice, Italy
Modified transthoracic echocardiographic imaging suffices to demonstrate presence and stable position of left atrial appendage closure devices
H. Simon, K. Simon Demel, A. Sallam, S. Mahfouz, E. Pellumbi, R. Hoffmann, R.O. Hoffmann / Aurich, Germany
New oral anticoagulants in complex adult congenital heart disease patients: a single centre experience
B. Sarubbi, G. Scognamiglio, A. Merola, A. Correra, M. D’Alto, E. Romeo, D. Colonna, G. Di Nardo, M.G. Russo / Naples, Italy
Ivabradine and atrial fibrillation: a word of caution?
T. Patel, A. Ivanov, K. Gondal, J. Heitner, G. Turitto / New York, USA
When the CHA2DS2Vasc score is not enough!
G. Marchetti, G. Penna, S. Urbinati / Bologna, Italy